shutterstock_1463056853_poptika
Poptika / Shutterstock.com
28 September 2021BiotechnologyMuireann Bolger

LSPN LIVE 2021: an ‘unmissable opportunity’

Over the past year, the life sciences sector has proved to be of vital importance in the fight against COVID-19. Now more than ever, it is imperative that IP professionals are best positioned to protect and leverage innovation in this fast-paced industry.

LSIPR welcomes IP professionals working in the life sciences arena to attend LSPN LIVE 2021: Protecting and leveraging innovation in the life sciences on October 5-7. Here, you can join more than 200 patent professionals to explore how to protect and capitalise on invaluable life sciences innovations. Make sure and secure your place now.

Following on from the hugely successful in-person LSPN conferences in Boston, London, Singapore and San Francisco, this three-day online conference takes a global view of the patent protection landscape and delves into today’s cutting-edge topics. More than half of LSPN LIVE attendees are in-house counsel.

An ‘unrivalled gathering’

Speaker Penny Gilbert, partner and founding member of law firm Powell Gilbert, described the conference as an “unmissable opportunity” for life sciences IP professionals.

“LSPN LIVE presents an unrivalled gathering of in-house patent counsel from established and fledgling pharmaceutical and biotechnology companies coming together to listen to updates on patent prosecution and enforceability,” she said.

“This is an invaluable opportunity for delegates to submit pressing questions, and source specialist IP attorneys to assist with constructing strong IP portfolio strategies for this year and beyond.”

Read more about the full agenda here.

Gilbert noted that in her session, “ Following Brexit, what practical steps can we continue to make to minimise patent risk for life sciences companies?” she and her fellow partner, Zoë Butler, will be providing an update on the extent to which Brexit has affected life sciences patents

She said: “There has been little, if any, substantive change to prosecuting and litigating patents, but there is a change to patent extension provisions (affecting the grant of supplementary patent certificates). Decisions by the Court of Justice of the European Union will also have an impact.”

She added that the UK’s withdrawal from the Agreement for a Unified Patent Court (UPC) is also likely to have significant implications for life sciences.

“We will be discussing how this affects life sciences companiesand particularly their European litigation strategies,” said Gilbert.

Critical issues

Other sessions will offer valuable insight into the sector issues of critical current importance, including:

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

article
1 February 2021   The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.
Big Pharma
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

More on this story

article
1 February 2021   The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.
Big Pharma
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.

More on this story

article
1 February 2021   The COVID-19 pandemic has brought into sharp relief the crucial role that universities play in cutting-edge innovation. One story of the past year is the collaboration between research institutions such as Oxford University, and commercial entities like AstraZeneca, to rapidly bring a life-saving product to market.
Big Pharma
15 February 2021   Chances are, if you manage a life sciences portfolio, you had to rethink your monetization strategy last year.